Xenon’s AZK Pushes Forward | Business and Finance News

Xenon Pharmaceuticals is on a roll, with their drug AZK poised for an NDA submission this quarter after a positive FDA meeting, and eyes set on expanding its use into epilepsy and even neuropsychiatry. Their pain programs targeting Kv7 and Nav1.7 channels show promising CNS penetration, offering non-opioid hope for chronic pain. Commercial momentum is strong, with healthcare providers and payers already singing AZK’s praises for efficacy, safety, and ease of use. With over $1 billion in cash reserves, Xenon is financially primed to launch AZK, fund ongoing trials, and push forward into 2029 — including key data expected in H1 2027 for depression and bipolar disorder studies. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/5ea5884f64270b3b